Successful mobilization of hematopoietic peripheral blood progenitor cells with paclitaxel-based chemotherapy as initial or salvage regimen in patients with hematologic malignancies

Fernández, Ángel Martínez; Arriba, Felipe de; Rivera, José; Heras, Inmaculada; Vicente, Vicente; Lozano, Marı́a Luisa

doi:10.3324/haematol.13056

Cited by 4 publications

(2 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…short term statin use, paclitaxel, certain β-blockers such as nebivolol and carvedilol; while others have a negative impact on mobilization ( e.g . bisphosphonates, long-term use of statins and trimethoprim/sulfamethoxazole) 40–46 . None of the medications listed in Table 1 had been started in the time frame while patients were receiving HBO 2 and all had been prescribed for over 2 months prior to patient enrollment.…”

Section: Discussionmentioning

confidence: 99%

CD34+/CD45-dim stem cell mobilization by hyperbaric oxygen — Changes with oxygen dosage

et al. 2014

View full text Add to dashboard Cite

Because hyperbaric oxygen treatment mobilizes bone marrow derived-stem/progenitor cells by a free radical mediated mechanism, we hypothesized that there may be differences in mobilization efficiency based on exposure to different oxygen partial pressures. Blood from twenty consecutive patients was obtained before and after the 1st, 10th and 20th treatment at two clinical centers using protocols involving exposures to oxygen at either 2.0 or 2.5 atmospheres absolute (ATA). Post-treatment values of CD34+, CD45-dim leukocytes were always 2-fold greater than the pre-treatment values for both protocols. Values for those treated at 2.5 ATA were significantly greater than the 2.0 ATA treatment group by factors of 1.9 to 3-fold after the 10th and before and after the 20th treatments. Intracellular content of hypoxia inducible factors -1,-2, and -3, thioredoxin-1 and poly-ADP-ribose polymerase assessed in permeabilized CD34+ cells with fluorophore-conjugated antibodies were twice as high in all post- versus pre-treatment samples with no significant differences between 2.0 and 2.5 ATA protocols. We conclude that putative progenitor cell mobilization is higher with 2.5 versus 2.0 ATA treatments, and all newly mobilized cells exhibit higher concentrations of an array of regulatory proteins.

show abstract

Section: Discussionmentioning

confidence: 99%

CD34+/CD45-dim stem cell mobilization by hyperbaric oxygen — Changes with oxygen dosage

et al. 2014

View full text Add to dashboard Cite

show abstract

“…Forty-nine patients with hematologic malignancies planned for autologous transplant (20 with lymphoma, 15 with multiple myeloma, and 14 with acute leukemia), who underwent mobilization of hematopoietic progenitor cells with paclitaxel 170 mg/m 2 i.v. by continuous infusion for 24 hours followed by 8 mg/kg s.c. recombinant human granulocyte colony-stimulating factor (rhG-CSF) daily, and that had leukapheresis product available, were included in the study (21). In this series, recruited between 1999 to 2008, the time elapsed from the last cytotoxic treatment was at least 3 weeks, to allow recovery of peripheral blood counts before paclitaxel administration.…”

Section: Methodsmentioning

confidence: 99%

Hematologic β-Tubulin VI Isoform Exhibits Genetic Variability That Influences Paclitaxel Toxicity

et al. 2012

View full text Add to dashboard Cite

Cellular microtubules composed of a-b-tubulin heterodimers that are essential for cell shape, division, and intracellular transport are valid targets for anticancer therapy. However, not all the conserved but differentially expressed members of the b-tubulin gene superfamily have been investigated for their role in these settings. In this study, we examined roles for the hematologic isoform b-tubulin VI and functional genetic variants in the gene. b-tubulin VI was highly expressed in blood cells with a substantial interindividual variability (seven-fold variation in mRNA). We characterized DNA missense variations leading to Q43P, T274M, and R307H, and a rare nonsense variant, Y55X. Because variations in the hematologic target of microtubule-binding drugs might alter their myelosuppressive action, we tested their effect in cell lines stably expressing the different b-tubulin VI full-length variants, finding that the T274M change significantly decreased sensitivity to paclitaxel-induced tubulin polymerization. Furthermore, patients treated with paclitaxel and carrying b-tubulin VI T274M exhibited a significantly lower thrombocytopenia than wild-type homozygous patients (P ¼ 0.031). Together, our findings define b-tubulin VI as a hematologic isotype with significant genetic variation in humans that may affect the myelosuppresive action of microtubule-binding drugs. A polymorphism found in a tubulin isoform expressed only in hemapoietic cells may contribute to the patient variation in myelosuppression that occurs after treatment with microtubule-binding drugs. Cancer Res; 72(18); 4744-52. Ó2012 AACR.

show abstract

Milk-derived exosomes for oral delivery of paclitaxel

Agrawal

Aqil

Jeyabalan

et al. 2017

Nanomedicine: Nanotechnology, Biology and Medicine

427

296

View full text Add to dashboard Cite

Successful mobilization of hematopoietic peripheral blood progenitor cells with paclitaxel-based chemotherapy as initial or salvage regimen in patients with hematologic malignancies

Cited by 4 publications

References 9 publications

CD34+/CD45-dim stem cell mobilization by hyperbaric oxygen — Changes with oxygen dosage

CD34+/CD45-dim stem cell mobilization by hyperbaric oxygen — Changes with oxygen dosage

Hematologic β-Tubulin VI Isoform Exhibits Genetic Variability That Influences Paclitaxel Toxicity

Milk-derived exosomes for oral delivery of paclitaxel

Contact Info

Product

Resources

About